FORGE Life Science was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs use the host's immune system to fight cancer, FORGE antivirals use the host cell's intrinsic immunity to defend against infection. The vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug resistance, and provide unique broad-spectrum treatment modalities. This will transform the practice of medicine because FORGE products address the infectious disease condition as opposed to targeting a specific virus-type. Multiple assets and indications (via underlying validated platform technology) enables strategic partnering to minimize burn and maximize exit opportunities by acquisition, while progressing internal value creation through an orphan drug path.